This is an unusual pharmaceutical - a drug that is alive and can multiply once inside the body. The redesigned cells are multiplied in the laboratory, and millions or billions of them are put back into the patient’s bloodstream, set loose like a vast army of tumor assassins. The patient’s T-cells, the soldiers of the immune system, are extracted from the patient’s blood, then genetically engineered to recognize and destroy cancer. The technique, known as cell therapy, gives each patient an individualized and souped-up version of their own immune system, one that “works better than nature made it,” as Dr. Now, versions of the therapy for a limited number of blood cancers are nearing approval by federal regulators, and could reach the market as early as next year. Michel Sadelain of Memorial Sloan Kettering Cancer Center have been at the forefront of this research for decades, laboring in separate labs in an intense sometimes-cooperative, sometimes-competitive pursuit to bring to fruition a daring therapy that few colleagues believed would work. June of the University of Pennsylvania and Dr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |